Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1

Area of Science:

• Molecular Biology
• Biochemistry
• Structural Biology

Background:

• Apoptosis is vital for tissue homeostasis and inflammation control in multicellular organisms.
• Dysregulation of apoptosis, particularly Mcl-1 (myeloid cell leukaemia 1) overexpression, is common in cancers, promoting cell survival.
• Mcl-1 is a key anti-apoptotic protein and a promising target for cancer drug development.

Purpose of the Study:

• To discover and characterize an antibody fragment targeting Mcl-1.
• To demonstrate the utility of this fragment in creating a crystal system for structure-guided drug design.
• To facilitate the development of novel therapeutics that restore apoptosis in cancer cells.

Main Methods:

• Discovery of an anti-Mcl-1 antibody fragment (scFv and Fab).
• Biophysical characterization of the antibody fragment.
• Generation of an Mcl-1 crystal system using the antibody fragment.

Main Results:

• Successful identification and characterization of an anti-Mcl-1 antibody fragment.
• Demonstration of the fragment's utility in forming a crystal system.
• Establishment of a platform for iterative structure-guided drug design against Mcl-1.

Conclusions:

• The anti-Mcl-1 antibody fragment is a valuable tool for structural studies.
• This approach enables structure-guided drug design targeting Mcl-1.
• Restoring Mcl-1 inhibition offers a potential therapeutic strategy for cancer treatment.